Matching articles for "Lipitor"
Issue 1756 · June 8, 2026
Drugs for Hypercholesterolemia

Recently published multisociety guidelines for the management of dyslipidemia emphasize early identification and treatment of dyslipidemia to reduce the lifetime risk of atherosclerotic cardiovascular disease…

Med Lett Drugs Ther. 2026 Jun 8; 68(1756):89-95 doi:10.58347/tml.2026.1756a
Recently published multisociety guidelines for the management of dyslipidemia emphasize early identification and treatment of dyslipidemia to reduce the lifetime risk of atherosclerotic cardiovascular disease (ASCVD) and death.
Issue 1756 · June 8, 2026
Comparison Chart: Statins (online only)

View the Comparison Chart: Statins

Med Lett Drugs Ther. 2026 Jun 8; 68(1756):e94-5 doi:10.58347/tml.2026.1756b
View the Comparison Chart: Statins
Issue 1659 · September 19, 2022
Comparison Table: Some Lipid-Lowering Drugs (online only)

View the Comparison Table: Some Lipid-Lowering Drugs

Med Lett Drugs Ther. 2022 Sep 19; 64(1659):e152-6
View the Comparison Table: Some Lipid-Lowering Drugs
Issue 1623 · May 3, 2021
Evinacumab (Evkeeza) for Homozygous Familial Hypercholesterolemia

The FDA has approved evinacumab-dgnb ( Evkeeza – Regeneron), an angiopoietin-like 3 (ANGPTL3) inhibitor, for adjunctive IV treatment of homozygous familial hypercholesterolemia (HoFH) in patients ≥12 years…

Med Lett Drugs Ther. 2021 May 3; 63(1623):66-7
The FDA has approved evinacumab-dgnb ( Evkeeza – Regeneron), an angiopoietin-like 3 (ANGPTL3) inhibitor, for adjunctive IV treatment of homozygous familial hypercholesterolemia (HoFH) in patients ≥12 years old. Evinacumab is the first ANGPTL3 inhibitor to be approved in the US.
Issue 1595 · April 6, 2020
Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol

The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone ( Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption…

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):53-5
The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone ( Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe (Nexlizet) as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-cholesterol (LDL-C). Bempedoic acid is the first ACL inhibitor to be approved in the US.
Issue 1581 · September 23, 2019 Free
Expanded Table: Statins (online only)

View the Expanded Table: Statins

Med Lett Drugs Ther. 2019 Sep 23; 61(1581):e152
View the Expanded Table: Statins
Issue 1565 · February 11, 2019
Lipid-Lowering Drugs

Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their recommendations.

Med Lett Drugs Ther. 2019 Feb 11; 61(1565):17-24
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their recommendations.
Issue 1565 · February 11, 2019
Expanded Table: Lipid-Lowering Drugs (online only)

View the Expanded Table: Lipid-Lowering Drugs

Med Lett Drugs Ther. 2019 Feb 11; 61(1565):e24-30
View the Expanded Table: Lipid-Lowering Drugs
Issue 1549 · June 18, 2018 Free
In Brief: Pitavastatin Magnesium (Zypitamag) for Hyperlipidemia

The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium ( Zypitamag – Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):106
The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium ( Zypitamag – Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin magnesium bioequivalent to pitavastatin calcium (Livalo) , which was approved in 2009. 1 Statins remain the treatment of choice for most patients who require lipid-lowering therapy. Taken as an adjunct to diet modification, increased exercise, and smoking cessation, statins can reduce the risk of primary and secondary cardiovascular events and death in patients with or at high risk for atherosclerotic cardiovascular disease. 2 Even in patients at low risk for cardiovascular disease, treatment with a statin can significantly reduce the incidence of cardiovascular events. 3 Controlled trials in patients with cardiovascular disease have shown that high-intensity statin therapy (defined as reducing LDL-cholesterol [LDL-C] by ≥50% on average) reduces the incidence of cardiac events, stroke, and coronary death significantly more than less intensive regimens. In one meta-analysis, each additional 1 mmol/L (39 mg/dL) reduction in LDL-C was associated with a 20% reduction in major vascular events and a 10% reduction in all-cause mortality. 4 In a randomized trial in 13,054 Japanese patients with stable coronary artery disease, over a median follow-up of 3.9 years, patients taking pitavastatin calcium 4 mg daily were significantly less likely than those taking 1 mg daily to have a cardiovascular event (4.3% vs 5.4%). 5 Approval of pitavastatin magnesium was based on the results of trials with pitavastatin calcium; no new efficacy trials were required. The Medical Letter's review of pitavastatin calcium concluded that recommended doses of the drug had not been shown to decrease LDL-C more than other statins with longer safety records and there was no good reason to use it. That conclusion applies to pitavastatin magnesium as well. Pitavastatin (Livalo) – the seventh statin. Med Lett Drugs Ther 2010; 52:57. Lipid-lowering drugs. Med Lett Drugs Ther 2016; 58:133. CTT Collaboration et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581. CTT Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670. I Taguchi et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation 2018; 137:1997. Download complete U.S. English article
Issue 1513 · January 30, 2017
Drug Interaction: Dabigatran (Pradaxa) and Statins

The results of a recently published study suggest that taking the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa) with either simvastatin ( Zocor , and others) or lovastatin ( Altoprev , and…

Med Lett Drugs Ther. 2017 Jan 30; 59(1513):26
The results of a recently published study suggest that taking the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa) with either simvastatin ( Zocor , and others) or lovastatin ( Altoprev , and others) increases the risk of major hemorrhage.
Issue 1506 · October 24, 2016
Lipid-Lowering Drugs

Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of…

Med Lett Drugs Ther. 2016 Oct 24; 58(1506):133-40
Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of most patients who require lipid-lowering therapy.
Issue 1475 · August 17, 2015
Alirocumab (Praluent) to Lower LDL-Cholesterol

The FDA has approved the subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor alirocumab ( Praluent – Sanofi/Regeneron) as an adjunct to diet and maximally tolerated statin…

Med Lett Drugs Ther. 2015 Aug 17; 57(1475):113-5
The FDA has approved the subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor alirocumab ( Praluent – Sanofi/Regeneron) as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol (LDL-C). It was not approved for general use in statin-intolerant patients. Alirocumab is the first PCSK9 inhibitor to be approved in the US. Evolocumab ( Repatha – Amgen), another PCSK9 inhibitor, was recently approved in Europe and has been recommended for approval for the same indications in the US by an FDA Advisory Committee.
Issue 1446 · July 7, 2014
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.

Med Lett Drugs Ther. 2014 Jul 7; 56(1446):53-8
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Issue 1433 · January 6, 2014
Simeprevir (Olysio) for Chronic Hepatitis C

The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir ( Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination…

Med Lett Drugs Ther. 2014 Jan 6; 56(1433):1-2
The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir ( Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination with peginterferon and ribavirin for treatment of chronic HCV genotype 1 infection in adults with compensated liver disease. Telaprevir (Incivek) and boceprevir (Victrelis) were approved in 2011 for the same indication. Sofosbuvir ( Sovaldi – Gilead), a nucleotide analog polymerase inhibitor that has been approved for use with and without interferon for treatment of multiple HCV genotypes, will be reviewed in the next issue of The Medical Letter .
Issue 137 · January 1, 2014
Drugs for Lipids

HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL…

Treat Guidel Med Lett. 2014 Jan; 12(137):1-6
HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL receptors, which in turn increases uptake and clearance of LDL-C from the blood. Statins also lower very low-density lipoprotein cholesterol (VLDL-C) and triglycerides. Most statins increase high-density lipoprotein cholesterol (HDL-C), but only modestly.
Issue 1419 · June 24, 2013
Liptruzet: A Combination of Ezetimibe and Atorvastatin

The FDA has approved a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe and the HMG-CoA reductase inhibitor (statin) atorvastatin as Liptruzet (Merck) for treatment of hyperlipidemia.…

Med Lett Drugs Ther. 2013 Jun 24; 55(1419):49-50
The FDA has approved a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe and the HMG-CoA reductase inhibitor (statin) atorvastatin as Liptruzet (Merck) for treatment of hyperlipidemia. Ezetimibe is also available in a fixed-dose combination with simvastatin (Vytorin) .
Issue 1370 · August 8, 2011
New Simvastatin Dosing Recommendations

The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months…

Med Lett Drugs Ther. 2011 Aug 8; 53(1370):61-2
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone ( Zocor , and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor) .
Issue 103 · March 1, 2011
Drugs for Lipids

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. Lipid-regulating drugs must be taken…

Treat Guidel Med Lett. 2011 Mar; 9(103):13-20
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels in 2-3 weeks.
Issue 97 · September 1, 2010
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals…

Treat Guidel Med Lett. 2010 Sep; 8(97):65-70
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals is discussed in the text that follows. Some drugs are recommended here for indications that have not been approved by the FDA.
Issue 1343 · July 26, 2010
Pitavastatin (Livalo) - The Seventh Statin

The FDA has approved the marketing of pitavastatin ( Livalo – Kowa), an HMG-CoA reductase inhibitor (“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in…

Med Lett Drugs Ther. 2010 Jul 26; 52(1343):57-8
The FDA has approved the marketing of pitavastatin ( Livalo – Kowa), an HMG-CoA reductase inhibitor (“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in Japan since 2003. All of the statins now available in the US are listed in the table on page 58.
Issue 1317 · July 27, 2009
When a Statin Fails

The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.

Med Lett Drugs Ther. 2009 Jul 27; 51(1317):58-60
The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.
Issue 1297 · October 20, 2008
Drug Interactions with Simvastatin

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became…

Med Lett Drugs Ther. 2008 Oct 20; 50(1297):83-4
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin ( Lipitor ) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.
Issue 1284 · April 21, 2008
Which Statin?

Advertisements for atorvastatin (Lipitor) , the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a…

Med Lett Drugs Ther. 2008 Apr 21; 50(1284):29-31
Advertisements for atorvastatin (Lipitor) , the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much lower retail price or lower co-pay than atorvastatin.
Issue 66 · February 1, 2008
Drugs for Lipids

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for…

Treat Guidel Med Lett. 2008 Feb; 6(66):9-16
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for lifestyle changes; a combination of diet, exercise and lipid-lowering drugs is optimal for prevention of coronary disease. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoprotein levels return to pretreatment levels in 2-3 weeks.
Issue 1243 · September 11, 2006 Free
In Brief: Atorvastatin for Stroke Prevention

Statins have been shown to reduce the risk of stroke in patients at high risk for cardiovascular disease (Treat Guidel Med Lett 2005; 3:15) . A recent issue of The New England Journal of Medicine includes the…

Med Lett Drugs Ther. 2006 Sep 11; 48(1243):75-6
Statins have been shown to reduce the risk of stroke in patients at high risk for cardiovascular disease (Treat Guidel Med Lett 2005; 3:15) . A recent issue of The New England Journal of Medicine includes the results of a study sponsored by the manufacturer in which 80 mg of atorvastatin ( Lipitor – Pfizer) or placebo was given to 4731 patients without coronary artery disease who had had a stroke or transient ischemic attack (TIA) within one to six months before study entry (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels [SPARCL] Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549) . Patients were not required to have elevated cholesterol levels to enroll. The authors conclude that the study results support starting atorvastatin treatment soon after a stroke or TIA. The primary study endpoint was a nonfatal or fatal stroke. During a median follow-up of 4.9 years, patients treated with atorvastatin had 265 strokes compared to 307 strokes with placebo. Patients treated with atorvastatin had 56 fewer ischemic strokes and 22 more hemorrhagic strokes. They also had 39 fewer coronary events. There were 216 deaths among patients treated with atorvastatin and 211 among those treated with placebo. Whether patients with a recent ischemic stroke or TIA would be as well protected against a recurrence and against coronary events by a lower dose of atorvastatin or by another less potent statin remains to be determined. The risk of myopathy and rhabdomyolysis with statins is dose-related; atorvastatin is the second-most potent statin on the US market (rosuvastatin is the most potent), and 80 mg is its maximum dose. Statins have an antithrombotic effect, and an increase in hemorrhagic stroke in patients with cerebrovascular disease treated with statins has been reported previously (Heart Protection Collaborative Study, Lancet 2004; 363:757) . It is doubtful whether patients with a recent hemorrhagic stroke should be treated with statins at all, let alone a maximum dose of atorvastatin. Download U.S. English
Issue 1225 · January 2, 2006
Statins for High-Risk Patients without Heart Disease or High Cholesterol

The FDA recently approved the use of atorvastatin (Lipitor) to reduce the risk of heart attack and stroke in patients without heart disease who have type 2 diabetes plus other risk factors, with or without…

Med Lett Drugs Ther. 2006 Jan 2; 48(1225):1-2
The FDA recently approved the use of atorvastatin (Lipitor) to reduce the risk of heart attack and stroke in patients without heart disease who have type 2 diabetes plus other risk factors, with or without hypercholesterolemia. The agency also approved the drug's use to reduce the risk of stroke in high-risk nondiabetic patients without heart disease, whether or not they have hypercholesterolemia. Similar indications were previously approved for simvastatin (Zocor).
Issue 1212 · July 4, 2005
CYP3A and Drug Interactions

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in…

Med Lett Drugs Ther. 2005 Jul 4; 47(1212):54-5
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo .
Issue 31 · March 1, 2005
Drugs for Lipids

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. In controlled trials in patients with…

Treat Guidel Med Lett. 2005 Mar; 3(31):15-22
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. In controlled trials in patients with coronary disease, some of these drugs have reduced mortality by 20% to 30%.
Issue 1196 · November 22, 2004
Safety of Aggressive Statin Therapy

New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high…

Med Lett Drugs Ther. 2004 Nov 22; 46(1196):93-5
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Issue 1195 · November 8, 2004
Tablet Splitting

Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose…

Med Lett Drugs Ther. 2004 Nov 8; 46(1195):89-91
Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose between marketed strengths. When 2 tablet sizes cost the same, as they often do, splitting the larger size saves money. Is this a reasonable practice?
Issue 1189 · August 16, 2004
Telithromycin (Ketek) for Respiratory Infections

Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in…

Med Lett Drugs Ther. 2004 Aug 16; 46(1189):66-8
Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in patients age 18 and older. The drug is the first in a new class of antibiotics, the ketolides, derived from the macrolide erythromycin. Telithromycin has been marketed in Europe since 2001.
Issue 1182 · May 10, 2004
Cholesterol Rethink for High-Risk Patients

The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been…

Med Lett Drugs Ther. 2004 May 10; 46(1182):37-9
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
Issue 1167 · October 13, 2003
Rosuvastatin - a New Lipid-lowering Drug

Rosuvastatin ( Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol…

Med Lett Drugs Ther. 2003 Oct 13; 45(1167):81-3
Rosuvastatin ( Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol levels. Rosuvastatin, like other statins, inhibits the enzyme that catalyzes the rate-limiting step in cholesterol synthesis, but it is claimed to be more potent than the others. All of these drugs must be taken indefinitely; if they are discontinued, lipid levels return to baseline.
Issue 12 · August 1, 2003
Drugs For Lipid Disorders

Drugs that lower low-density lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and also improve vasodilatation. In controlled…

Treat Guidel Med Lett. 2003 Aug; 1(12):77-82
Drugs that lower low-density lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and also improve vasodilatation. In controlled trials in patients with coronary disease, they have reduced mortality by 30% to 40%. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipid levels return to pretreatment levels in 2-3 weeks.
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 1151 · March 3, 2003
Three New Drugs for Hyperlipidemia

The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia ) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol.…

Med Lett Drugs Ther. 2003 Mar 3; 45(1151):17-9
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia ) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin ( Mevacor , and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Issue 1115 · October 15, 2001 Free
Generic Lovastatin - Note

Because of a last minute change in an FDA ruling, generic lovastatin will not be available until after December 15, contrary to the statement in the September 17 Medical Letter article on Substituing for…

Med Lett Drugs Ther. 2001 Oct 15; 43(1115):90
Because of a last minute change in an FDA ruling, generic lovastatin will not be available until after December 15, contrary to the statement in the September 17 Medical Letter article on Substituing for Cerivastatin (vol. 23, page 79)
Issue 1113 · September 17, 2001
Substituting For Cerivastatin (Baycol)

Full-page newspaper advertisements are urging patients with high cholesterol levels who are stopping Baycol (cerivastatin) to ask their doctors about Pravachol (pravastatin), Lipitor (atorvastatin), Zocor…

Med Lett Drugs Ther. 2001 Sep 17; 43(1113):79-80
Full-page newspaper advertisements are urging patients with high cholesterol levels who are stopping Baycol (cerivastatin) to ask their doctors about Pravachol (pravastatin), Lipitor (atorvastatin), Zocor (simvastatin) or Lescol (fluvastatin). Some advertisements come with a coupon for free medication. Lovastatin, which is available generically, has not appeared in similar advertisements. Cerivastatin was withdrawn from the market on August 8 because of post-marketing reports of 31 cases of fatal rhabdomyolysis.
Issue 1105 · May 28, 2001
Choice of Lipid-Regulating Drugs

New recommendations for drug treatment of hypercholesterolemia, if widely followed, will lead to a marked increase in the number of people taking lipid-regulating drugs.

Med Lett Drugs Ther. 2001 May 28; 43(1105):43-8
New recommendations for drug treatment of hypercholesterolemia, if widely followed, will lead to a marked increase in the number of people taking lipid-regulating drugs.
Issue 1091 · October 30, 2000
Colesevelam (Welchol) For Hypercholesterolemia

Colesevelam hydrochloride ( Welchol - Sankyo Pharma), a nonabsorbed hydrophilic polymer that binds bile acids, has been approved by the FDA for reduction of plasma LDL cholesterol in patients with primary…

Med Lett Drugs Ther. 2000 Oct 30; 42(1091):102-4
Colesevelam hydrochloride ( Welchol - Sankyo Pharma), a nonabsorbed hydrophilic polymer that binds bile acids, has been approved by the FDA for reduction of plasma LDL cholesterol in patients with primary hypercholesterolemia.
Issue 1042 · December 18, 1998
Choice of Lipid-lowering Drugs

Drugs that lower-density-lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, improve coronary vasodilatation, and decrease…

Med Lett Drugs Ther. 1998 Dec 18; 40(1042):117-22
Drugs that lower-density-lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, improve coronary vasodilatation, and decrease mortality from coronary heart disease. All of these drugs must be continued indefinitely; when they are stopped, plasma cholesterol concentrations generally return to pretreatment levels. Elevated serum triglyceride concentrations appear to be an independent risk factor for cardiovascular disease in both women and men, but direct evidence of clinical benefit from triglyceride reduction is lacking.
Issue 1030 · July 3, 1998
Fenofibrate for Hypertriglyceridemia

Micronized fenofibrate ( Tricor - Abbott), a fibric acid derivative structurally similar to clofibrate ( Atromid-S , and others) and gemfibrozil ( Lopid , and others), has been approved by the FDA for…

Med Lett Drugs Ther. 1998 Jul 3; 40(1030):68-9
Micronized fenofibrate ( Tricor - Abbott), a fibric acid derivative structurally similar to clofibrate ( Atromid-S , and others) and gemfibrozil ( Lopid , and others), has been approved by the FDA for treatment of hypertriglyceridemia. Increased serum triglyceride concentrations have been associated with an increased risk of coronary heart disease (J Jeppesen et al, Circulation, 97:1029, 1998).
Issue 1018 · January 16, 1998
Cerivastatin for Hypercholesterolemia

Cerivastatin ( Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl…

Med Lett Drugs Ther. 1998 Jan 16; 40(1018):13-4
Cerivastatin ( Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic acid.